Loading...
XSHE
002675
Market cap1.50bUSD
Jul 09, Last price  
12.37CNY
1D
-1.51%
1Q
-10.94%
Jan 2017
-13.50%
IPO
119.72%
Name

Yantai Dongcheng Pharmaceuticl Gp Co Ltd

Chart & Performance

D1W1MN
XSHE:002675 chart
P/E
52.14
P/S
3.75
EPS
0.24
Div Yield, %
0.24%
Shrs. gr., 5y
0.55%
Rev. gr., 5y
-4.45%
Revenues
2.72b
-5.10%
323,389,253376,458,482663,628,430857,573,000587,753,813774,730,022751,021,851794,915,7781,158,450,7361,595,601,1362,332,822,9372,992,761,0113,418,977,5483,912,049,9953,582,955,4263,275,647,8862,868,936,5372,722,602,760
Net income
196m
+6.42%
15,065,07031,988,49350,639,117127,935,000105,057,610100,849,525103,957,98589,745,426130,952,619172,633,610280,426,757154,714,678417,765,801151,561,409307,291,221209,735,783183,825,713195,628,901
CFO
585m
+103.59%
41,567,800-26,602,00057,017,000138,826,00044,535,000-20,603,00052,002,00066,688,000196,281,000208,935,000493,063,000696,376,000572,577,000943,581,000996,537,000276,945,000287,151,000584,610,592
Dividend
May 27, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.
IPO date
May 25, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT